Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited
Cancer discovery, 2021•AACR
Published series on COVID-19 support the notion that patients with cancer are a particularly
vulnerable population. There is a confluence of risk factors between cancer and COVID-19,
and cancer care and treatments increase exposure to the virus and may dampen natural
immune responses. The available evidence supports the conclusion that patients with
cancer, in particular with hematologic malignancies, should be considered among the very
high-risk groups for priority COVID-19 vaccination.
vulnerable population. There is a confluence of risk factors between cancer and COVID-19,
and cancer care and treatments increase exposure to the virus and may dampen natural
immune responses. The available evidence supports the conclusion that patients with
cancer, in particular with hematologic malignancies, should be considered among the very
high-risk groups for priority COVID-19 vaccination.
Summary
Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.
AACR
